A drug for pre-exposure prophylaxis against HIV has been prepared for annual administration.
Vamshi Jogiraju and colleagues at Gilead Sciences reported the success of a phase I clinical trial of lenacapavir as a single-injection, yearly pre-exposure prophylaxis for HIV infection. As follows…